Somewhat Positive Media Coverage Somewhat Unlikely to Impact Esperion Therapeutics (ESPR) Share Price

News headlines about Esperion Therapeutics (NASDAQ:ESPR) have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Esperion Therapeutics earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.3898493505735 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

ESPR has been the subject of several research reports. Stifel Nicolaus restated a “buy” rating and issued a $70.00 target price (up from $60.00) on shares of Esperion Therapeutics in a research note on Thursday, August 10th. Deutsche Bank AG set a $64.00 target price on Esperion Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 9th. Jefferies Group LLC upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating and reduced their target price for the company from $85.00 to $55.00 in a research note on Tuesday, August 8th. UBS AG restated a “buy” rating and issued a $57.00 target price (up from $52.00) on shares of Esperion Therapeutics in a research note on Tuesday, June 27th. Finally, BidaskClub upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, June 25th. Seven equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $52.54.

Esperion Therapeutics (NASDAQ ESPR) traded down 0.12% during trading on Monday, hitting $50.33. 307,745 shares of the company’s stock traded hands. Esperion Therapeutics has a 12 month low of $9.40 and a 12 month high of $57.38. The stock’s market cap is $1.14 billion. The company’s 50 day moving average is $47.73 and its 200-day moving average is $39.69.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.67) by $0.25. During the same quarter in the previous year, the firm posted ($0.62) EPS. On average, analysts predict that Esperion Therapeutics will post ($7.29) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was first published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.themarketsdaily.com/2017/09/11/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-esperion-therapeutics-espr-share-price.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Insider Buying and Selling by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply